Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹200 | ₹100 |
Expense Ratio | 2.45 | 1.86 |
NAV | ₹29.55 | ₹40.22 |
Fund Started | 08 Feb 2019 | 25 Jun 2018 |
Fund Size | ₹87.59 Cr | ₹6437.36 Cr |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -3.28% | 3.31% |
3 Year | 19.23% | 26.49% |
5 Year | 12.83% | 18.90% |
1 Year
3 Year
5 Year
Equity | 97.10% | 97.10% |
Cash | 2.90% | 2.90% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.39% |
Apollo Hospitals Enterprise Ltd. | 5.90% |
Cipla Ltd. | 5.35% |
Torrent Pharmaceuticals Ltd. | 5.34% |
Fortis Healthcare Ltd. | 4.92% |
Divi's Laboratories Ltd. | 4.74% |
Neuland Laboratories Ltd. | 4.54% |
Piramal Pharma Ltd. | 4.52% |
Aurobindo Pharma Ltd. | 4.07% |
Alkem Laboratories Ltd. | 3.91% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.88% |
Dr. Reddy's Laboratories Ltd. | 9.42% |
Divi's Laboratories Ltd. | 8.50% |
Aurobindo Pharma Ltd. | 7.62% |
Cipla Ltd. | 6.61% |
Lupin Ltd. | 5.40% |
Alkem Laboratories Ltd. | 3.98% |
Biocon Ltd. | 3.28% |
Mankind Pharma Ltd. | 2.79% |
Zydus Lifesciences Ltd. | 2.67% |
Name | Karan Doshi | Dharmesh Kakkad |
Start Date | 31 Oct 2025 | 23 Feb 2021 |
Name
Start Date
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 08 Feb 2019 | 25 Jun 2018 |
Description
Launch Date